Page 1

rocket pharma Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP - A501 under the modified pivotal Phase 2 protocol completed the protocol - defined safety observation period ; no thrombotic microangiopathy , capillary leak syndrome , or other significant safety concerns observed Rocket is actively engaging with the FDA to align on the path to rapidly completing the pivotal Phase 2 trial in Danon disease Multiple clinical and regulatory milestones remain on track for the second half of 2026 , including a broader Danon disease program update , a regulatory update for the planned RP - A601 pivotal study in PKP2 - ACM and initial patient dosing with RP - A701 in BAG3 - DCM FDA approval of KRESLADI ™ and subsequent monetization of the Priority Review Voucher generated $ 180 million in non - dilutive capital ; focused preparations are underway for commercial availability and patient onboarding beginning in the fourth quarter of 2026 Cash , cash equivalents and investments of approximately $ 283.7 million ; expected cash runway into the second quarter of 2028 CRANBURY , NJ – August 10 , 2026 – Rocket Pharmaceuticals , Inc. ( NASDAQ : RCKT ) , a fully integrated , commercial - stage biotechnology company advancing a sustainable pipeline of genetic medicines for rare disorders with high unmet need , today reported financial and recent operational results for the second quarter ended June 30 , 2026 . - - " The second quarter of 2026 materially strengthened Rocket's position , with the approval of KRESLADI demonstrating our ability to advance a genetic medicine through regulatory approval , the subsequent sale of the Priority Review Voucher generating $ 180 million in non - dilutive capital , and safety clearance for the first three Danon disease patients in our modified pivotal trial , ” said Gaurav Shah , M.D. , Chief Executive Officer of Rocket Pharmaceuticals . “ Together with the more focused operating structure we implemented in late 2025 , these achievements provide a stronger financial and executional foundation for advancing our cardiovascular pipeline . Based on the positive safety observations in Danon disease , we are working with the FDA on the path to treating additional patients and completing the pivotal trial as quickly as possible , while progressing toward additional regulatory and clinical milestones across the remainder of our cardiac portfolio , including PKP2 - ACM and BAG3 - DCM . "